pharmaphorum

NOVEMBER 3, 2021

A real-world study of digital therapeutic (DTx) for opioid use disorder has found that patient show used it had 46% fewer hospital stays than a control group, saving more than $2,700 over a nine-month period. The study of Pear Therapeutics’ reSET-O found that the total cost of hospital and clinician costs were $11,141 among 64 patients who were prescribed the DTx but didn’t use it, but fell to $8,733 among active users of the 12-week course.

Hospitals 130

Hospitals 130

Pharma Times

NOVEMBER 5, 2021

The trial evaluated the investigational medicine in non-hospitalised adult patients with COVID-19 who are at high-risk of progressing to severe illness

126

126

NY Times

OCTOBER 30, 2021

It was the state’s first lethal injection since 2015, when it halted executions after using the wrong drug in one instance and allowing a prisoner to regain consciousness in another.

98

98

Drug Channels

NOVEMBER 2, 2021

Open enrollment is under way for the 2022 Medicare Part D plans. Our exclusive analysis of Center for Medicare & Medicaid Services’ (CMS) data reveals that preferred cost sharing pharmacy networks will maintain their dominance as an established component of Part D benefit design. For 2022: 98% of stand-alone Medicare Part D prescription drug plans (PDP) will have a preferred network. 66% of Medicare Advantage prescription drug (MA-PD) plans will have a preferred network.

Independent Pharmacies 91

Independent Pharmacies 91

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

pharmaphorum

NOVEMBER 5, 2021

An oral antiviral drug developed by Pfizer has been shown to dramatically cut the risk of hospitalisation or death from COVID-19 when given in the early stages of infection. The phase 3 trial found that Paxlovid – which combines new protease inhibitor PF-07321332 with already-approved HIV drug ritonavir – reduced the risk of hospitalisation or death by 89% when given to newly-diagnosed adults who were at risk of developing severe COVID-19 in the EPIC-HR trial.

Hospitals 110

Hospitals Drug Development 110

Pharma Times

NOVEMBER 2, 2021

93% of clinicians felt that remote medicine was worse than in-person consultations in terms of accuracy

123

123

Outsourcing Pharma

NOVEMBER 1, 2021

The cloud software firmâs Digital Clinical Trials Survey Report reveals that the industry is adapting to challenges caused by COVID-19 and other factors.

91

91

pharmaphorum

NOVEMBER 1, 2021

Novartis has claimed FDA approval for one of its ‘wild card’ drugs – Scemblix – a first-in-class STAMP inhibitor for patients with previously-treated chronic myeloid leukaemia (CML). Scemblix (asciminib) was one of a clutch of high risk, high reward drug candidates for a range of diseases that Novartis chief executive Vas Narasimhan said last year were flying under-the-radar of industry watchers, but could potentially develop into blockbusters.

Labelling 106

Labelling 106

Pharma Times

NOVEMBER 1, 2021

HRT treats menopause symptoms by replacing hormones that are at a lower level for those experiencing it

122

122

NY Times

NOVEMBER 4, 2021

Start-up investors have often suspended skepticism while chasing a hot deal. The trial of Ms. Holmes, the founder of Theranos, has put that behavior under the spotlight.

80

80

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management

Outsourcing Pharma

NOVEMBER 1, 2021

A former employee of Tellus Clinical Research in Miami has admitted to charges related to a conspiracy to falsify data on a list of clinical drug trials.

85

85

pharmaphorum

NOVEMBER 5, 2021

Novartis has chalked up another successful trial for its targeted factor B inhibitor iptacopan, an orally-active drug trying to challenge antibody-based therapies for diseases associated with the complement pathway. A phase 2 trial of iptacopan in patients with the rare kidney disease C3 glomerulopathy (C3G) – which causes progressive kidney failure and has no approved treatments – showed reductions in kidney damage with the drug that Novartis said were “clinically important.” C3G of

104

104

Pharma Times

NOVEMBER 1, 2021

Anyone who received their second dose at least six months ago can now receive their booster at one of these sites

113

113

NY Times

NOVEMBER 2, 2021

In one of the first cases to be brought against drug manufacturers over the crisis, a judge ruled that there was “simply no evidence” the companies were liable in the epidemic.

77

77

Outsourcing Pharma

NOVEMBER 1, 2021

The trial will evaluate a weekly regimen of islatravir and lnecapavir in HIV patients who are virologically suppressed while on antiretroviral therapies.

76

76

pharmaphorum

NOVEMBER 4, 2021

After more than 20 years, Novartis has finally decided to sell its substantial share in fellow Swiss pharma group Roche for $20.7 billion, a decent return on its original $5 billion investment. The agreement will see Novartis lose its one-third voting share stake in Roche, after agreeing to sell 53.3 million Roche bearer shares at their average price over 20 days prior to 2 November, when the deal was agreed.

103

103

Pharma Times

NOVEMBER 4, 2021

Partnership will establish an in-house liquid biopsy testing service, using Guardant Health’s proprietary digital sequencing platform

101

101

NY Times

NOVEMBER 4, 2021

The authorization of Merck’s easy-to-use Covid treatment, molnupiravir, is a step toward taming the pandemic.

95

95

Outsourcing Pharma

NOVEMBER 2, 2021

The global pharmaceutical industry event is returning to the real world November 9-11 this year, with online content for professionals opting not to travel.

72

72

pharmaphorum

NOVEMBER 4, 2021

Routine vaccination with human papillomavirus vaccines have resulted in an 87% reduction in cervical cancer cases in England, and could even see the need for smear tests phased out in future, according to a new study. The jabs with have been offered by the NHS to girls between the ages of 12 and 13 since 2008, with more than 10 million doses administered since then, and from September 2019 was also offered to boys in the same age group.

Vaccines 100

Vaccines 100

Pharma Times

NOVEMBER 3, 2021

Back in 2019, esketamine was commercialised as Spravato, described as a “breakthrough” medication used to treat depression

101

101

Drug Channels

NOVEMBER 5, 2021

Today’s guest post comes from Ashleigh Burdette, Senior Director of Clinical Innovation at Biologics by McKesson. Ashleigh explains how biopharma companies can help patients become more adherent and achieve better health outcomes by partnering with an experienced specialty pharmacy that offers risk-based care. . To learn more about the risk-based care approach, download the free whitepaper: Risk-Based Care Helps Cancer Treatment Adherence.

Specialty Pharmacies 69

Specialty Pharmacies 69

NY Times

OCTOBER 30, 2021

Most Medicare beneficiaries don’t compare plans during open enrollment season, and may be paying more, or accepting more restrictions, than they should.

69

69

pharmaphorum

NOVEMBER 2, 2021

Rocketing sales of COVID-19 vaccine Comirnaty have allowed Pfizer to raise its full-year forecasts for the shot once again to a whopping $36 billion, more than double its predictions just a few months ago. Fuelled by extensions to vaccination programmes to include children and booster shots, the BioNTech-partnered jab made nearly $13 billion in the third quarter, around $2 billion more than analyst consensus forecasts.

Vaccines 98

Vaccines 98

Pharma Times

NOVEMBER 4, 2021

The research paper, published in the Lancet and funded by Cancer Research UK, considered all cervical cancers diagnosed in England among women aged 20-64 between January 2006 and June 2019

Vaccines 83

Vaccines 83

Drug Patent Watch

NOVEMBER 4, 2021

Annual Drug Patent Expirations for MYCAPSSA Mycapssa is a drug marketed by Chiasma and is included in one NDA. It is available from one supplier. There are seven patents protecting…. The post New patent for Chiasma drug MYCAPSSA appeared first on DrugPatentWatch - Make Better Decisions.

59

59

NY Times

OCTOBER 30, 2021

Most Medicare beneficiaries don’t compare plans during open enrollment season, and may be paying more, or accepting more restrictions, than they should.

66

66

pharmaphorum

NOVEMBER 4, 2021

Two kidney transplant patients who received a stem cell therapy developed by Talaris Therapeutics were able to come off all immunosuppressant drugs within a year, without any evidence of graft rejection. The first findings from Talaris’ phase 3 trial of the cell therapy – called FCR001 – suggest it may be possible to eliminate the need entirely for patients to take what may be dozens of tablets daily after organ transplants , according to the US biotech.

Immunity 98

Immunity Immunization 98

Pharma Times

NOVEMBER 3, 2021

Dunad will apply its own platform to generate the novel covalent and targeted protein degrading small molecule drugs

103

103

Drug Patent Watch

NOVEMBER 4, 2021

Annual Drug Patent Expirations for SAVELLA Savella is a drug marketed by Allergan and is included in one NDA. It is available from three suppliers. There are four patents protecting…. The post New patent expiration for Allergan drug SAVELLA appeared first on DrugPatentWatch - Make Better Decisions.

59

59

Outsourcing Pharma

NOVEMBER 2, 2021

An expert from the specialty chemicals firm (and CPhI Worldwide speaker) explains trends and developments in excipients and how they drive advancements.

59

59

pharmaphorum

NOVEMBER 3, 2021

The EMA has started its review of AstraZeneca and Daiichi Sankyo’s Enhertu for a second indication, as a second-line treatment for HER2-positive gastric cancer. If approved the new indication for antibody-drug conjugate Enhertu (trastuzumab deruxtecan) will add to its first EU approval in advanced HER2-positive breast cancer after two or more HER2-targeted therapies.

Chemotherapy 97

Chemotherapy Biosimilars Labelling 97

Pharma Times

NOVEMBER 4, 2021

The antiviral medicine will be marketed with the trademark name Lagevrio in the UK

114

114

Drug Patent Watch

NOVEMBER 1, 2021

Annual Drug Patent Expirations for TECFIDERA Tecfidera is a drug marketed by Biogen Inc and is included in one NDA. It is available from one supplier. There are seven patents…. The post New patent for Biogen Inc drug TECFIDERA appeared first on DrugPatentWatch - Make Better Decisions.

59

59

Pharma Marketing Network

NOVEMBER 4, 2021

Jim Lefevere is an award-winning highly-influential agile intrapreneur with over 20 years of expertise in the consumer goods, startups, medical device, and healthcare industries. Jim has enjoyed a very diverse and successful career with progressive growth in leadership, global marketing, digital marketing, and strategy development. Jim is a visionary intrapreneur at a global scale as a social media pioneer, digital health scholar, and agile leader.

52

52